[go: up one dir, main page]

PT3302454T - Composições para utilização no tratamento da doença de parkinson e distúrbios associados - Google Patents

Composições para utilização no tratamento da doença de parkinson e distúrbios associados

Info

Publication number
PT3302454T
PT3302454T PT167344811T PT16734481T PT3302454T PT 3302454 T PT3302454 T PT 3302454T PT 167344811 T PT167344811 T PT 167344811T PT 16734481 T PT16734481 T PT 16734481T PT 3302454 T PT3302454 T PT 3302454T
Authority
PT
Portugal
Prior art keywords
disease
compositions
related disorders
treating parkinson
parkinson
Prior art date
Application number
PT167344811T
Other languages
English (en)
Original Assignee
Technophage Investig E Desenvolvimento Em Biotecnologia Sa
Lusomedicamenta S A
LABORATORIO MEDINFAR PRODUTOS FARMACAªUTICOS S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage Investig E Desenvolvimento Em Biotecnologia Sa, Lusomedicamenta S A, LABORATORIO MEDINFAR PRODUTOS FARMACAªUTICOS S A filed Critical Technophage Investig E Desenvolvimento Em Biotecnologia Sa
Publication of PT3302454T publication Critical patent/PT3302454T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT167344811T 2015-05-26 2016-05-25 Composições para utilização no tratamento da doença de parkinson e distúrbios associados PT3302454T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562166531P 2015-05-26 2015-05-26

Publications (1)

Publication Number Publication Date
PT3302454T true PT3302454T (pt) 2021-04-01

Family

ID=56322267

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167344811T PT3302454T (pt) 2015-05-26 2016-05-25 Composições para utilização no tratamento da doença de parkinson e distúrbios associados

Country Status (9)

Country Link
US (1) US10471025B2 (pt)
EP (1) EP3302454B1 (pt)
JP (1) JP6853791B2 (pt)
CN (1) CN107660147B (pt)
AU (1) AU2016266432B2 (pt)
CA (1) CA2986891C (pt)
ES (1) ES2869981T3 (pt)
PT (1) PT3302454T (pt)
WO (1) WO2016190766A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019357036B2 (en) * 2018-10-11 2024-11-14 Indivior Uk Limited Buprenorphine to treat respiratory depression
CN113473983B (zh) * 2018-12-24 2024-07-23 索伦托药业有限公司 通过施用树脂毒素治疗帕金森病的方法
WO2022101227A1 (en) * 2020-11-10 2022-05-19 Integrative Research Laboratories Sweden Ab [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias
US20240164699A1 (en) * 2021-03-17 2024-05-23 Offxet S.R.L. Device for predicting the wearing-off conditions in a patient affected by parkinson's disease
CN112933117B (zh) * 2021-04-28 2023-04-07 遵义医科大学 一种预防和/或治疗帕金森病的药物及其应用
JP2024520132A (ja) * 2021-06-04 2024-05-21 トランスポゾン セラピューティクス インコーポレイテッド 向知性薬としてのline-1阻害剤
CN113422876B (zh) * 2021-06-24 2022-05-10 广西电网有限责任公司 基于ai的电力客服中心辅助管理方法、系统及介质
WO2023019351A1 (en) * 2021-08-16 2023-02-23 University Health Network Methods and compositions for treating alpha-synuclein-mediated neurodegeneration
CN116832066B (zh) * 2023-08-08 2024-01-12 青岛海洋生物医药研究院股份有限公司 乌贼墨提取物在制备抗多动症和抗抑郁症药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DK1539135T3 (da) * 2002-09-17 2007-09-17 Motac Neuroscience Ltd Behandling af dyskinesi
US20100316712A1 (en) 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
NZ586361A (en) * 2007-11-23 2012-09-28 Gruenenthal Chemie Tapentadol compositions
CN102105169B (zh) 2008-06-06 2014-09-10 图必制药公司 用于治疗帕金森病的药物组合物
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
PH12013501244A1 (en) * 2010-12-28 2013-07-15 Euro Celtique Sa A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
WO2012136351A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for treating pain associated with trigeminal neuralgia
ES2646363T3 (es) * 2011-04-29 2017-12-13 Grünenthal GmbH Tapentadol para la prevención y el tratamiento de la depresión y la ansiedad
EP2970160B1 (en) * 2013-03-15 2020-11-11 Melior Pharmaceuticals II, LLC Methods of treating dyskinesia and related disorders

Also Published As

Publication number Publication date
AU2016266432A1 (en) 2017-11-09
CN107660147B (zh) 2021-04-30
WO2016190766A1 (en) 2016-12-01
CN107660147A (zh) 2018-02-02
US20180147160A1 (en) 2018-05-31
EP3302454B1 (en) 2021-03-10
CA2986891C (en) 2022-01-04
JP2018515549A (ja) 2018-06-14
ES2869981T3 (es) 2021-10-26
EP3302454A1 (en) 2018-04-11
CA2986891A1 (en) 2016-12-01
JP6853791B2 (ja) 2021-03-31
US10471025B2 (en) 2019-11-12
AU2016266432B2 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
IL274648A (en) Promote new catecholamine drugs for use in the treatment of Parkinson's disease
PT3302454T (pt) Composições para utilização no tratamento da doença de parkinson e distúrbios associados
LT3889145T (lt) 8-ciano-5-piperidin-chinolinai, kaip tlr7/8 antagonistai ir jų panaudojimas gydant imuninius sutrikimus
IL277182A (en) Compositions and methods for treating Parkinson's disease
IL263188B (en) Treatment for Parkinson's disease
AU2022271491B2 (en) Antisense oligonucleotides for use in treating alzheimer's disease
SMT202200151T1 (it) Composizioni e metodi per l’uso nel trattamento di omocistinuria.
EP3554496A4 (en) METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
IL274203A (en) A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease
PL3352742T3 (pl) Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona
IL265656A (en) Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease
EP3256151A4 (en) Methods and compositions for treating muscle disease and disorders
EP3162377A4 (en) Use of -asarone in preparing drugs for preventing and treating alzheimer's disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
GB201603510D0 (en) Compositions for use in the treatment of neurological disease
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
ZA201807944B (en) Treatment for parkinson's disease
HK40012465A (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
HK40013419A (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
GB201504144D0 (en) Treatment of Parkinson's disease